Included in the formulation
Included in the list (Order of the Government of the Russian Federation No. 2782-r of 30.12.2014):ONLS
АТХ:
R.03.B.B Holinblockers
Pharmacodynamics:Competitively blocks peripheral and central M-, H-holinoretseptory. Reduces the tone of the smooth muscles of the gastrointestinal tract and urinary tract. Strengthens contractility of the myometrium, in the first period of labor removes spasm of the cervix, contributing to its opening.
Pharmacokinetics:Not studied.
Indications:It is used to relieve spasm of smooth muscles in diseases of the gastrointestinal tract and urinary system, with spasms of cerebral vessels, endarteritis, secondary weakness of labor.
Contraindications:Glaucoma, acute hepatic and renal insufficiency, prostatic hyperplasia.
Individual intolerance.
Carefully:Used with caution in children under 6 years.
Pregnancy and lactation:Pregnancy and lactation: recommendations for Food and Drug Administration (US Food and Drug Administration) - the code is not defined. Data on penetration into breast milk is not available.
Dosing and Administration:It is administered subcutaneously, intramuscularly (1% solution) and taken internally in tablets (25 mg).
The dose is set individually, depending on the clinical manifestations of the disease. Inside after a meal of 25 mg 2-4 times a day.Parenterally, 0.5-1 ml of a 1% solution subcutaneously or intramuscularly.
The highest daily dose: 100 mg for oral administration, 60 mg for parenteral administration.
The highest single dose: 30 mg - inside, 60 mg - parenterally.
Side effects:Central and peripheral nervous system: sedative effect, disruption of coordination of movements, accommodation.
Digestive system: thirst, dry mouth, indigestion, constipation.
The urinary system is the retention of urine.
Organs of vision: increased intraocular pressure.
Allergic reactions.
Overdose:Visual disturbances, difficulty breathing, unstable walking, dizziness, drowsiness, hallucinations, suppression of the vasomotor and respiratory center.
Treatment: intravenous injection of physostigmine 0.5-2 mg at a rate of not more than 1 mg per minute. The total dose is not more than 5 mg per day.
Interaction:Reduction of sedation is observed when caffeine is administered: 0.1-0.2 g orally or subcutaneously: 1 ml of a 20% solution.
Special instructions:Monitoring of liver function (laboratory tests: alanine aminotransferase, aspartate aminotransferase, bilirubin), intraocular pressure.
With Parkinson's disease motor disorders are reduced, but mental disorders are aggravated.
It affects attention and coordination of movements: it is assigned to patients whose occupations are associated with increased concentration of attention, only when they are released from work.